AstraZeneca ( (AZN) ) has released its Q4 earnings. Here is a breakdown of the information AstraZeneca presented to its investors.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
AstraZeneca is a leading global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in oncology, cardiovascular, renal & metabolism, and respiratory & immunology. Known for its extensive pipeline and collaborations, AstraZeneca operates in a dynamic and competitive industry.
In its full-year and fourth-quarter 2024 results, AstraZeneca reported strong financial performance, showcasing a 21% increase in total revenue and a 19% rise in Core EPS. The company highlighted significant growth across its key therapy areas, underpinned by robust product sales and strategic alliances.
Key financial metrics demonstrated substantial growth, with total revenue reaching $54,073 million for the year, driven by a 19% surge in product sales. Notably, the oncology segment grew by 24%, while the cardiovascular, renal & metabolism sector saw a 20% rise. The company also achieved milestones in its collaboration revenues, which more than doubled in the fourth quarter. Additionally, a second interim dividend of $2.10 per share was declared, contributing to a total annual dividend increase of 7%.
Strategically, AstraZeneca advanced its pipeline with nine positive phase III studies and secured multiple regulatory approvals in major global markets. These achievements, coupled with an anticipated high single-digit percentage increase in revenue and a low double-digit percentage rise in Core EPS for 2025, position the company favorably for future growth.
Looking forward, AstraZeneca’s management remains optimistic about maintaining its growth momentum, supported by a strong pipeline and increasing demand for its medicines across key regions. The company continues to invest in transformative technologies, aiming to achieve $80 billion in total revenue by 2030, reflecting its commitment to innovation and market leadership.
